This company listing is no longer active
ALPHE Stock Overview
Pherecydes Pharma Société anonyme develops antibacterial treatments based on the use of bacteriophage viruses or phages.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Pherecydes Pharma Société anonyme Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.00 |
52 Week High | €4.36 |
52 Week Low | €1.72 |
Beta | 0.99 |
1 Month Change | -0.99% |
3 Month Change | -18.70% |
1 Year Change | -53.60% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -79.38% |
Recent News & Updates
Recent updates
Shareholder Returns
ALPHE | FR Biotechs | FR Market | |
---|---|---|---|
7D | 2.6% | 1.1% | 0.2% |
1Y | -53.6% | -3.3% | 8.6% |
Return vs Industry: ALPHE underperformed the French Biotechs industry which returned -25.4% over the past year.
Return vs Market: ALPHE underperformed the French Market which returned 18.9% over the past year.
Price Volatility
ALPHE volatility | |
---|---|
ALPHE Average Weekly Movement | 6.0% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.3% |
10% most volatile stocks in FR Market | 9.4% |
10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALPHE's share price has been volatile over the past 3 months.
Volatility Over Time: ALPHE's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 29 | Thibaut Fayet | https://www.pherecydes-pharma.com |
Pherecydes Pharma Société anonyme develops antibacterial treatments based on the use of bacteriophage viruses or phages. It develops a portfolio of therapeutics, such as anti-staphylococcus aureus for the treatment of bone/joint and diabetic foot ulcer infections; anti-pseudomonas aeruginosa, a phage therapy treatment for respiratory tract infections; and anti-escherichia coli for the treatment of respiratory tract infections. The company was founded in 2006 and is headquartered in Romainville, France.
Pherecydes Pharma Société anonyme Fundamentals Summary
ALPHE fundamental statistics | |
---|---|
Market cap | €14.44m |
Earnings (TTM) | -€4.85m |
Revenue (TTM) | €3.16m |
4.6x
P/S Ratio-3.0x
P/E RatioIs ALPHE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALPHE income statement (TTM) | |
---|---|
Revenue | €3.16m |
Cost of Revenue | €5.42m |
Gross Profit | -€2.27m |
Other Expenses | €2.59m |
Earnings | -€4.85m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Sep 19, 2023
Earnings per share (EPS) | -0.67 |
Gross Margin | -71.91% |
Net Profit Margin | -153.85% |
Debt/Equity Ratio | 33.7% |
How did ALPHE perform over the long term?
See historical performance and comparison